Serum adipokine levels in type 1 diabetic patients: Association with carotid intima media thickness

Metabolic Syndrome and Related Disorders

Volumn 10, Issue 1, 2012, Pages 26-31

  Yazící, Dilek ^a   Yavuz, Dilek ^a   Öǧünç, Ayliz Velioǧlu ^b   Şirikçi, Önder ^a   Toprak, Ahmet ^a   Deyneli, Oǧuzhan ^a   Akalín, Sema ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LEPTIN; RESISTIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO;

ADIPOKINES; ADIPONECTIN; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LEPTIN; LIPIDS; MALE; RESISTIN; RISK ASSESSMENT; RISK FACTORS; TURKEY; ULTRASONOGRAPHY, DOPPLER; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84856060079     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2011.0052     Document Type: Article

References (37)

1. Krolewski AS, Kosinski EJ, Warram JH et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59: 750-755. (Pubitemid 17061281)
2. Soedamah-Muthu SS, Chaturvedi N, Toeller M et al.; EURODIAB Prospective Complications Study Group. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: The EURODIAB Prospective Complications Study. Diabetes Care 2004;27:530-537. (Pubitemid 38174083)
3. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 2007;30:707-712. (Pubitemid 46354357)
4. Orchard TJ, Olson JC, Erbey JR et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003;26:1374-1379. (Pubitemid 36929165)
5. Huerta MG. Adiponectin and leptin: Potential tools in the differential diagnosis of pediatric diabetes? Rev Endocr Metab Disord 2006;7:187-196 (Pubitemid 46072642)
6. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004;89:2563-2568 (Pubitemid 38766332)
7. Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002;277:25863-25866. (Pubitemid 34967064)
8. Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adipo-nectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-1737. (Pubitemid 38489895)
9. Siegrist-Kaiser CA, Pauli V, Juge-Aubry CE et al. Direct effects of leptin on brown and white adipose tissue. J Clin Invest 1997;100:2858-2864. (Pubitemid 28007556)
10. Kieffer TJ, Habener JF. The adipoinsular axis: Effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 2000;278:E1-E14. (Pubitemid 30101914)
11. Leyva F, Godsland IF, Ghatei M et al. as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998;18:928-933. (Pubitemid 28272587)
12. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312. (Pubitemid 32151228)
13. Kawanami D, Maemura K, Takeda N et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004;314:415-419. (Pubitemid 38084733)
14. Verma S, Li SH, Wang CH et al. Resistin promotes endo-thelial cell activation: Further evidence of adipokine-endothelial interaction. Circulation 2003;108:736-740. (Pubitemid 36999260)
15. Youn BS, Yu KY, Park HJ et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89:150-156. (Pubitemid 38183874)
16. Hasegawa G, Ohta M, Ichida Y et al. Increased serum re-sistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Dia-betol 2005;42:104-109. (Pubitemid 40881116)
17. Frystyk J, Tarnow L, Hansen TK et al. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005;48:1911-1918. (Pubitemid 41317848)
18. Imagawa A, Funahashi T, Nakamura T et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002;25:1665-1666
19. Hadjadj S, Aubert R, Fumeron F et al.; SURGENE Study Group; DESIR Study Group. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia 2005;48:1088-1092. (Pubitemid 40909643)
20. Orchard TJ, Dorman JS, Maser RE et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990;39:1116-1124. (Pubitemid 20263324)
21. Roden M, Ludwig C, Nowotny P et al. Relative hypolepti-nemia in patients with type 1 and type 2 diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:976-981. (Pubitemid 30618116)
22. Fehmann HC, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res 2002;34:671-673. (Pubitemid 36398705)
23. Schäffler A, Bü chler C, Mü ller-Ladner U et al. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res 2004;36:702-707. (Pubitemid 39486971)
24. Schalkwijk CG, Chaturvedi N, Schram MT et al.; EURO-DIAB Prospective Complications Study Group. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006;91:129-135. (Pubitemid 43069128)
25. Abd El-Maksoud AM, El Hefnawy MH et al. Early predictors of microvascular complications in type 1 diabetic patients. Clin Biochem 2009;42:1401-1406.
26. Jorsal A, Tarnow L, Frystyk J et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type 1 diabetes and diabetic nephropathy. Kidney Int 2008;74:649-654.
27. Shetty GK, Economides PA, Horton ES et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-2457. (Pubitemid 39281400)
28. Costacou T, Zgibor JC, Evans RW et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2005;48:41-48. (Pubitemid 40174655)
29. Tan KC, Xu A, Chow WS et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodila-tion. J Clin Endocrinol Metab 2004;89:765-769. (Pubitemid 38269891)
30. Fernández-Real JM, Castro A, Vázquez G et al. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 2004;27:739-745. (Pubitemid 38280543)
31. Atabek ME, Kurtoglu S, Demir F et al. Relation of serum leptin and insulin-like growth factor-1 levels to intima-media thickness and functions of common carotid artery in children and adolescents with type 1 diabetes. Acta Paediatr 2004; 93:1052-1057. (Pubitemid 39452785)
32. Williams KV, Erbey JR, Becker D et al. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000;49:626-632. (Pubitemid 30183752)
33. Pajvani UB, Du X, Combs TP et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003;278:9073-9085. (Pubitemid 36800387)
34. Kowalska I, Straczkowski M, Nikoajuk A et al. Plasma adiponectin and E-selectin concentrations in patients with coronary heart disease and newly diagnosed disturbances of glucose metabolism. Adv Med Sci 2006;51:94-97.
35. Leth H, Andersen KK, Frystyk J et al. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab 2008;93:3186-3191.
36. Reilly MP, Iqbal N, Schutta M et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004;89:3872-3878. (Pubitemid 39071487)
37. On YK, Park HK, Hyon MS et al. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007;71:868-873.